Myleran (Busulfan)

Busulfan alkylates DNA, creating cross‑links that prevent DNA replication and transcription. This DNA damage leads to apoptosis of rapidly dividing cells, particularly malignant hematopoietic cells, providing its antineoplastic effect.

The dosage of Myleran is individualized and determined by the prescribing physician based on the specific indication, patient weight, organ function, and treatment protocol. Patients should follow the prescriber’s instructions precisely.

Busulfan is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should only be used during pregnancy if the potential benefit justifies the risk. Breastfeeding is not recommended while receiving Busulfan because it can be excreted in milk.

To order Myleran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Busulfan is a widely used alkylating agent for conditioning because of its predictable pharmacokinetics and potent myeloablative effect. Compared with total body irradiation or other alkylators such as cyclophosphamide, Busulfan offers a purely chemical approach, but may carry higher risks of pulmonary and hepatic toxicity, requiring careful monitoring.

Myleran capsules should be stored at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, heat and direct sunlight to maintain stability and potency.

Myleran is taken orally as a capsule. The exact schedule—single dose, divided doses, or continuous administration—depends on the treatment protocol prescribed by the oncologist or transplant specialist.

Serious risks include pulmonary fibrosis, hepatic veno‑occlusive disease, severe bone‑marrow suppression leading to pancytopenia, and seizures at high plasma concentrations. Prompt medical attention is required if any of these complications arise.

Myleran should be avoided in patients with known hypersensitivity to Busulfan, severe hepatic impairment, uncontrolled infections, or in pregnant women unless the benefit outweighs the risk. It is also contraindicated when used concurrently with other strong alkylating agents without specialist supervision.